Paul Kinnon - President, Chief Executive Officer
Paul Kinnon was appointed President and Chief Executive Officer of Transgenomic in September, 2013. Mr. Kinnon has more than 20 years of global leadership experience in innovative life science and diagnostics companies. Between January and August, 2013, he provided consulting services to the life science sector as a Partner at Arch Global Research. In this role, Mr. Kinnon conducted comprehensive strategic reviews of a number of life science companies and developed a deep understanding of the opportunities and challenges facing the companies. From January 2007 to December 2012, Mr. Kinnon was President, CEO and a Director of ZyGEM Corp. From May 2006 until June 2007, Mr. Kinnon was Vice President & General Manager Environmental Diagnostics at high growth life sciences and diagnostics firm Invitrogen. From October, 2004 until April, 2006, Mr. Kinnon was Vice President, Global Strategic Alliances at Invitrogen. From January 2003 until October 2004, Mr. Kinnon was Vice President of Sales & Marketing at Guava Technologies, Inc. From January 2000 through the end of 2003, Mr. Kinnon was Vice President, Sales, and in 1999-2000 he was European Manager, for Cellomics, Inc. From 1996 – 1999, Mr. Kinnon was Sales & Marketing Director at Porvair Sciences, Ltd. Earlier, Mr. Kinnon held marketing and sales positions of increasing responsibility in a number of technology-based companies. He began his career as an analytical chemist at a predecessor company of GlaxoSmithKline.
Mark Colonnese - Chief Financial Officer
Mr. Colonnese has nearly 30 years of experience in leading business growth and financial strategies for life sciences companies. He most recently served as Executive Vice President, Commercial Operations and Chief Financial Officer at Salutria Pharmaceuticals, LLC, a privately-held, development-stage pharmaceutical company. Prior to that, Mr. Colonnese served as Executive Vice President, Commercial Operations at AtheroGenics, Inc., a development-stage pharmaceutical company, where he raised $450 million in debt and equity capital, led the company’s IPO in 2000 and helped negotiate a worldwide partnership agreement with AstraZeneca. Prior to joining AtheroGenics, Mr. Colonnese served as Senior Vice President and Chief Financial Officer at Medaphis Corporation and has also held executive positions at Applied Analytical Industries, Inc. and Schering-Plough Corporation. Mr. Colonnese holds an M.B.A. from Fairleigh Dickinson University, a B.S. magna cum laude from Ithaca College, and is a Certified Public Accountant.
Katrina Fahlin - Vice President of Quality
Katrina Fahlin is the Vice President of Quality for Transgenomic. She holds a B.S. degree in Professional Chemistry from South Dakota State University and has graduate work in chemistry from the University of Nebraska. Ms. Fahlin has more than 30 years of experience in the quality arena including thirteen years with Novartis in Quality Assurance. She is a qualified Lead Auditor and her regulatory experience includes ISO standards, and FDA experience with pharmaceuticals, feed, food, and food and feed additives. She has lead the successful efforts at Transgenomic to attain ISO 9001 certification for their instrument and bioconsumable business and the College of American Pathologist accreditation of the CLIA reference laboratory.
Katherine A. Richardson, Ph. D. - Vice President of Research and Development
Dr. Richardson is Vice President of Research and Development. She holds an S.B. degree in life sciences from the Massachusetts Institute of Technology and a Ph.D. in molecular cellular developmental biology from Iowa State University. Dr. Richardson has more than 25 years of molecular biology laboratory experience. She joins Transgenomic following eight years as a scientist with OSI Pharmaceuticals, where she specialized in molecular biology research and development in the area of oncology. Previously Dr. Richardson was with Eli Lilly and Company for nine years as a senior toxicologist specializing in genetic toxicology and molecular carcinogenesis. Dr. Richardson has to her credit nearly 60 publications, abstracts and presentations at scientific conferences, and she was part of the group at Eli Lilly that identified the link between the BRCA-1 gene and hereditary breast cancer.